Philogen S.p.A.
PHIL
Rank in Stocks
#10482
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic... Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.
Share Price
$23.85
Last synced: 2026-11-09
Market Cap
$688.74M
Change (1 day)
1.15%
Change (1 year)
-12.45%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Philogen S.p.A. (PHIL)
Category
Healthcare
Operating Margin for Philogen S.p.A. (PHIL)
Operating Margin as of November 2026 TTM: 79.26%
According to Philogen S.p.A.'s latest financial reports, its current operating margin (TTM) is 79.26%. At the end of 2025 the company had an operating margin of 80.04%.
Operating Margin history for Philogen S.p.A. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 79.26% | -0.97% |
| 2025 | 80.04% | 56.97% |
| 2024 | 50.99% | -233.41% |
| 2023 | -38.22% | -3,884.16% |
| 2022 | 1.01% | -100.15% |
| 2021 | -672.08% | 164.75% |
| 2020 | -253.85% | 632.61% |
| 2019 | -34.65% | -1,046.72% |
| 2018 | 3.66% | -123.11% |
| 2017 | -15.84% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.51% |
US
|
|
| -149.01% | -101.88% |
US
|
|
| 25.57% | -99.68% |
AU
|
|
| 31.23% | -99.61% |
BE
|
|
| 29.35% | -99.63% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Philogen S.p.A.'s operating margin
What is Philogen S.p.A.'s operating margin?
Philogen S.p.A.'s operating margin is 79.26%, as of Nov 2026.
What was Philogen S.p.A.'s operating margin in 2025?
In 2025, Philogen S.p.A.'s operating margin was 80.04%, compared with 50.99% in 2024.
How has Philogen S.p.A.'s operating margin changed since 2020?
From 2020 to 2025, Philogen S.p.A.'s operating margin was highest in 2025 (80.04%) and lowest in 2021 (-672.08%).
How does Philogen S.p.A.'s operating margin compare with similar companies?
Philogen S.p.A.'s operating margin (79.26%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.